Prosecution Insights
Last updated: October 21, 2026
Application No. 18/682,274

Method for Producing Compound, Compound, and Metal Catalyst

Non-Final OA §102§112
Filed
Feb 08, 2024
Priority
Aug 11, 2021 — JP 2021-131481 +1 more
Examiner
WITHERSPOON, SIKARL A
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Japan Science and Technology Agency
OA Round
1 (Non-Final)
86%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allowance Rate
1437 granted / 1666 resolved
+26.3% vs TC avg
Minimal -20% lift
Without
With
+-20.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
43 currently pending
Career history
1708
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
46.0%
+6.0% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
17.3%
-22.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1666 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 and 13-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Independent claim 1 is drawn to a method for preparing a compound of formula (1) by mixing ethylene, a compound of formula (2), and a compound of formula (3) to give a compound of formula (4). At the end of the reaction, the claim does not state that a compound of formula (1) is made. This causes some confusion as to whether compound (4) is actually the intended compound, or if there is a step missing that converts compound (4) to compound (1). Dependent claim 2-7 and 13-15 are also rejected as being indefinite, as they do not clarify the issue with the lack of clarity of the independent claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 16, 18, and 19 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Casey et al. (J. Amer. Chem. Soc., 1999). Casey et al. disclose DIPHOS derivatives used as ligands for rhodium complex catalysts for rhodium-catalyzed hydroformylation reactions (abstract; p. 64, 1st col.). This disclosure anticipates the instant claims. Claim(s) 17 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stoop et al. (Organometallics, 1999). Stoop et al. disclose BH3-containing diphosphines that anticipate the instant claim (p.5698, 2nd col.). Claims 8-12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SIKARL A WITHERSPOON whose telephone number is (571)272-0649. The examiner can normally be reached M-F 9am-9pm IFP. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SIKARL A WITHERSPOON/Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Feb 08, 2024
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767624
METHOD FOR PURIFYING CANNABINOID COMPOUNDS
3y 5m to grant Granted Oct 20, 2026
Patent 12767685
METHOD OF PREPARING ESTRADIOL DERIVATIVES BY SOLID-PHASE SYNTHESIS
3y 0m to grant Granted Oct 20, 2026
Patent 12741027
USE OF HIGH MOLECULAR WEIGHT HYALURONIC ACID AS OCULAR TRANSPORTING VEHICLE
3y 9m to grant Granted Sep 22, 2026
Patent 12735377
SPIN ON METAL-ORGANIC FORMULATIONS
2y 11m to grant Granted Sep 15, 2026
Patent 12735374
PREPARATION METHOD OF TRANS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE
2y 8m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
86%
Grant Probability
66%
With Interview (-20.1%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1666 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month